Kexing Biopharm Co., Ltd. (SHSE: 688136)
Health Care · Biotechnology · CN
CN¥20.55
-1.77% today · -55.0% 1Y
Kexing Biopharm Co., Ltd. (SHSE: 688136) operates in the Biotechnology industry within the Health Care sector. The company is valued at $604.85M and employs 1,048 people.
Over the last twelve months the share price has lost 55.0%, trading between 17.00 and 46.41.
Tweenvest scores Kexing Biopharm Co., Ltd. across four factors: quality 57/100, value 58/100, growth 60/100, dividend 6/100. Its strongest factor is growth.
688136 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $604.85M
- Revenue (TTM)
- $212.09M
- P/E
- 19.42
- EPS
- 1.06
- Dividend yield
- 1.22%
- Beta (5Y)
- 0.35
- 52-week high
- CN¥46.41
- 52-week low
- CN¥17.00
- Avg volume (3M)
- —
- Shares outstanding
- 197.86M
- Employees
- 1,048
- Next earnings
- —
About Kexing Biopharm Co., Ltd.
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
- ISIN
- CNE100006ZG6
- Founded
- 1997
- Listed since
- Dec 14, 2020
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.34 | +2.48% |
Figures last refreshed Aug 18, 2026.